US pharmaceutical company Eli Lilly (NYSE: LLY) has signed an agreement to acquire France-based Mablink Bioscience, a biotechnology firm specializing in next-generation antibody-drug conjugates (ADCs). This strategic move is set to enhance Eli Lilly’s capabilities in developing innovative oncology treatments through Mablink’s advanced ADC technology.
Mablink’s Proprietary ADC Technology
Mablink Bioscience’s proprietary technology utilizes hydrophilic linkers that enable the use of hydrophobic warheads in ADCs, resulting in a longer half-life in the body and a broader therapeutic index, as demonstrated in animal models. This technology is a significant advancement in the field of ADCs, offering a high drug-to-antibody ratio (DAR), favorable pharmacological properties, and improved tolerability.
Expanding Therapeutic Capabilities
The acquisition of Mablink Bioscience is expected to bolster Eli Lilly’s pipeline with ADCs that have the potential to address unmet medical needs. Mablink’s ADCs are designed to deliver targeted therapies with enhanced efficacy and safety profiles, making them a valuable addition to Eli Lilly’s oncology portfolio.
Deal Details and Regulatory Approval
Financial terms of the acquisition have not been disclosed, and the deal is subject to regulatory approval. Once finalized, the acquisition will mark a significant milestone in Eli Lilly’s ongoing efforts to innovate and expand its presence in the global biopharmaceutical market.-Fineline Info & Tech
